We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson & Johnson has been surprisingly successful at fending off Pfizer's Remicade biosimilar, and that didn't happen by accident. The pharma giant's upfront dealmaking and money-off pricing did the job.